SO THERAPIES: what changed
SO THERAPIES
Largest movements
- Cash +€5,799
up €5,799 (+414,186%), from €1 to €5,800
mainly Net result for the year (+€5,398) and Receivables within one year (+€874)
- Receivables within one year -€874
down €874 (-83.9%), from €1,042 to €168
of which Trade receivables: -€800
- Profit (loss) carried forward +€5,398
up €5,398, from -€4,346 to €1,053
- Trade debts -€874
down €874 (-70.6%), from €1,237 to €363
- Tax, wage and social debts +€341
new in 2025: €341
- Gross operating margin +€5,650
up €5,650 (+3,767%), from €150 to €5,800
- Taxes +€341
new in 2025: €341
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,043 | €5,968 | +€4,925 | +472% |
| Current assets | 29/58 | €1,043 | €5,968 | +€4,925 | +472% |
| Amounts receivable within one year | 40/41 | €1,042 | €168 | -€874 | -83.9% |
| Trade receivables | 40 | €800 | - | -€800 | |
| Other amounts receivable | 41 | €242 | €168 | -€74 | -30.4% |
| Cash at bank and in hand | 54/58 | €1 | €5,800 | +€5,799 | +414,186% |
| Total equity and liabilities | 10/49 | €1,043 | €5,968 | +€4,925 | +472% |
| Equity | 10/15 | -€3,346 | €2,053 | +€5,398 | |
| Contributions | 10/11 | €1,000 | €1,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€4,346 | €1,053 | +€5,398 | |
| Amounts payable | 17/49 | €4,388 | €3,915 | -€473 | -10.8% |
| Amounts payable within one year | 42/48 | €4,388 | €3,915 | -€473 | -10.8% |
| Trade debts | 44 | €1,237 | €363 | -€874 | -70.6% |
| Suppliers | 440/4 | €1,237 | €363 | -€874 | -70.6% |
| Taxes, remuneration and social security | 45 | - | €341 | +€341 | |
| Taxes | 450/3 | - | €341 | +€341 | |
| Other amounts payable | 47/48 | €3,152 | €3,211 | +€59 | +1.9% |
| Gross operating margin | 9900 | €150 | €5,800 | +€5,650 | +3,767% |
| Operating profit (loss) | 9901 | €150 | €5,800 | +€5,650 | +3,767% |
| Financial charges | 65/66B | €51 | €61 | +€10 | +18.9% |
| Recurring financial charges | 65 | €51 | €61 | +€10 | +18.9% |
| Profit (loss) for the period before taxes | 9903 | €99 | €5,739 | +€5,640 | +5,703% |
| Income taxes | 67/77 | - | €341 | +€341 | |
| Profit (loss) for the period | 9904 | €99 | €5,398 | +€5,299 | +5,358% |
| Profit (loss) for the period to be appropriated | 9905 | €99 | €5,398 | +€5,299 | +5,358% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 3 November 2026 via checked.be.